Generic Name and Formulations:
Sodium sulfate 17.5g, potassium sulfate 3.13g, magnesium sulfate 1.6g; per 6oz of soln.
Braintree Laboratories, Inc.
Indications for SUPREP:
Bowel cleansing before colonoscopy.
Start the evening before colonoscopy: dilute 1 bottle to 16oz with water and drink entire amount. Drink 32oz of water over the next hour. Next morning: repeat using the second bottle. Complete prep at least 2hrs before colonoscopy.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Maintain adequate hydration. Correct electrolyte abnormalities before use. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. History of QT prolongation, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. Gout. Seizure. Inflammatory bowel disease. Severe ulcerative colitis. Impaired gag reflex. Risk of regurgitation or aspiration. Pregnancy (Cat.C). Nursing mothers.
Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Caution with drugs that may increase risk of electrolyte abnormalities, arrhythmias or QT prolongation. Drugs administered within 1 hour of start of Suprep may not be absorbed.
Overall discomfort, abdominal distention and pain, nausea, vomiting; transient elevated uric acid, mucosal ulcerations and ischemic colitis.
Bowel prep kit—1 (2 x 6oz bottles of soln w. mixing container)
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine